Skip to main content
. Author manuscript; available in PMC: 2019 Mar 4.
Published in final edited form as: Nanomedicine. 2018 Jul 23;14(7):2179–2189. doi: 10.1016/j.nano.2018.07.008

Figure 3.

Figure 3.

DCE-MRI of control, MT-treated and sunitinib-treated tumors. (A) T1-weighted images were taken at different time points after iv injection of Gd-DTPA. (B) Relative signal intensity (%ΔS.I.) time curve of the ROI. (C) Ktrans – and Ve –mapping. (D) Ktrans and Ve changes after vasculature modification. * P<0.05, ** P<0.01.